Showing posts with label CIDRAP. Show all posts
Showing posts with label CIDRAP. Show all posts

Pakistan To Resume Polio Vaccinations

image

 

# 6822

 

 

Three times in recent weeks we’ve seen horrific coordinated attacks made against aid workers, either involved with or associated with the Polio Vaccination drives in Pakistan.

 

The first attack (see Pakistan: 6 Polio Workers Murdered) was reported on December 18th, the next day (see Pakistan: Fresh Attacks On WHO/UNICEF Polio Workers) we learned of 3 more deaths, and on January 1st  the headlines read : 7 More Aid Workers Killed In Pakistan.

 

 

Pakistan is one of 3 countries where the polio virus is still endemic (the others being Afghanistan and Nigeria).

 

Taliban leaders condemned polio immunization campaigns after the use of a sham hepatitis vaccination campaign as a CIA cover in the pursuit of Osama Bin Laden (see Maryn McKenna’s Update: Pakistan, Polio, Fake Vaccines And The CIA).

 

Today, news from Agence France-Presse that rather than reinstituting a high profile national vaccine campaign, small well-guarded teams will begin local, targeted and low profile vaccination campaigns.

 

Security measures include excluding female health workers from participating in some of the higher risk zones, and banning motorcycles in and around vaccination sites in an attempt to prevent drive-by shootings.

 

Follow the link below for further details from AFP.

 

Pakistan resumes polio vaccines under tight security

Published on 04 Jan 2013

 

 

For more perspective on why Pakistan’s vaccination program is considered so vital by many public health authorities, we have this excellent report by CIDRAP NEWS editor Robert Roos.

 

 

WHO says polio drive must push on despite Pakistan setbacks

Robert Roos * News Editor

Jan 3, 2013 (CIDRAP News) – In the wake of recent killings of polio vaccinators in Pakistan, some questions are being raised about the all-out push to eradicate polio, but the World Health Organization (WHO) says the world can't afford to back off on the eradication drive now.

 

"We've never had so few cases or such a small footprint of the virus, so we know this opportunity is not going to come back," Sona Bari, the WHO's polio eradication spokesperson, told CIDRAP News. "We've never been here before. It's now or never."

(Continue . . . )

 

The above is a small excerpt of a very long, and informative article. Well worth reading in its entirety.

»» Read More

CIDRAP News Coverage Of The H5N1 NIH Workshop

image

BSL-4 Lab Worker - Photo Credit –USAMRIID

 

 

# 6794

 

For the past couple of days researchers and policy makers have been meeting at the National Institutes of Health (NIH) to discuss the future of HHS funded H5N1 avian influenza gain-of-function studies – research that seeks to enhance the host range, transmissibility, or pathogenicity of the H5N1 virus.


Research of this type has been voluntarily suspended since very early this year when – due to a prolonged debate over the publication of a pair of controversial research papers (see The Furor Over H5N1 Research Continues) - a group of the world’s leading researchers announced a moratorium on specific types of bird flu research (see Scientists Announce 60 Day Moratorium On Some H5N1 Research).

 

Although not being webcast, Lisa Schnirring at CIDRAP NEWS has been providing excellent daily coverage of this NIH workshop. 

 

Follow the links below to get the details.

 

H5N1 researchers question proposed HHS funding framework

Lisa Schnirring * Staff Writer

Dec 17, 2012 (CIDRAP News) – Federal health officials are in the midst of crafting a framework for funding H5N1 avian influenza gain-of-function studies, and today at a workshop they heard varied feedback from researchers, biosecurity experts, and others.

 

The 2-day workshop, held at the National Institutes of Health (NIH), is the latest chapter in an intense scientific controversy that was triggered by the publication of two recent studies involving lab-engineered H5N1 strains that showed signs of being transmissible in mammals.

(Continue . . .)

 

 

Experts at NIH meeting say H5N1 research moratorium may end soon

Lisa Schnirring * Staff Writer

Dec 18, 2012 (CIDRAP News) – As a meeting to discuss issues related to federally funded H5N1 avian influenza research wrapped up today, experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon and said they sensed agreement about lab biosecurity levels.

 

The National Institutes of Health (NIH) held the 2-day meeting to gather feedback from flu researchers, others in the science community, and the public on its draft framework for funding H5N1 gain-of-function studies and to continue an international dialogue on issues related to benefits and risks of the research.

(Continue . . .)

»» Read More

Public Health Practices (PHP) Update

image

 

# 6785

 

 

Every few months I try to highlight the Public Health Practices project (formerly Promising Practices), a freely accessible repository of public health tools and strategies, sponsored by CIDRAP at the University of Minnesota, in partnership with the Association of State and Territorial Health Officials (ASTHO).

 

Over the past two years Public Health Practices has broadened its original scope to include more than just pandemic response. You’ll find tools and practices that cover a wide range of public health concerns, including chemical, radiological, and natural disasters.

 

image

 

In addition to the constantly expanding website, there is also a monthly email newsletter you can sign up for.

 

This continually expanding site includes:

  • More than 400 public health practices in 9 categories of emergency preparedness and disaster response from state and local health agencies, community-based organizations, and colleges and universities.

  • In-depth stories on how state and local projects were created, communications materials in more than 40 languages, and tools like job action sheets and media campaigns.

  • Expert reviewers' commentary on a practice's effectiveness, reach, sustainability, feasibility, and transferability. Please note: expert review is only available for a select number of practices.

  • A regular e-newsletter featuring our newest practices and other updates from the CIDRAP Public Health Practices staff.

  • The ability to search for practices based on geography, available languages, and key topics in preparedness and response.

Recent additions to the practices database include:

 

Recent Practices

2012 Dec 12

Community Reception Center exercise tests Florida’s radiological screening and decontamination process

State and local health departments across the country have been planning to address radiological threats, whether accidental (eg, incidents at nearby nuclear power plants) or manmade (eg,...

2012 Oct 16

Michigan integrates disaster preparedness curriculum into school health program

Disaster preparedness at the family level has been the focus of many public health agencies' communications campaigns. Recent collaborations between health agencies and school districts have...

2012 Oct 16

Social media training program builds responders' comfort with and ability to use Facebook and Twitter for emergency communications

Social media is used increasingly to alert, update, or provide recommendations to the public during emergencies. A 2011 American Red Cross (ARC) survey found that the Internet is the third most...

2012 Sep 17

Toolkit adapts infectious disease emergency response plan for local health departments

In 2006, the San Francisco Department of Public Health (SFDPH) compiled its Infectious Disease Emergency Response (IDER) plan. The IDER plan described how to integrate local emergency management and...

2012 Sep 17

Dispense Assist online screening system helps Kansas county improve POD throughput, serve vulnerable populations

More than 70 US cities participate in the Cities Readiness Initiative (CRI), which is funded by CDC to develop programs that ensure medication is available to a city's entire population within 48...

 

Whether you are looking for a specific solution, or simply looking for muse to inspire your organization’s emergency preparedness efforts, visiting Public Health Practicesand returning often – will likely pay tremendous dividends.

 

Highly recommended.

»» Read More

Referral: CIDRAP News Summarizes The Coronavirus Story

image

Coronavirus – Credit CDC PHIL


# 6648

 

Yesterday Robert Roos, News Editor at CIDRAP News, undertook a difficult assignment; taking the often fragmentary (and sometimes contradictory) reports on the 7 confirmed (and 1 suspected) coronavirus cases in the Middle East - and putting them into a coherent narrative. 

 

Extremely well done, and highly recommended.

 

 

WHO cites 7th coronavirus case, gives surveillance guidance

Robert Roos * News Editor

Nov 29, 2012 (CIDRAP News) – A third case in a family cluster of novel coronavirus infections has been confirmed, raising the global case count to seven, and the fourth illness in the family is now listed as a probable case, the World Health Organization (WHO) has announced.

 

In a statement dated yesterday, the WHO also indicated that only one death has been attributed to the novel virus so far, contradicting a Nov 23 announcement that reported two deaths among the first six cases.

(Continue . . . )

»» Read More

Peter Sandman On the CCIVI Vaccine Report

 

image

# 6638

 

Two days ago Michael Osterholm and his group at CIDRAP released their 160-page Comprehensive Influenza Vaccine Initiative (CCIVI) report, that among other things, cited longstanding overstatement of the effectiveness of the seasonal flu vaccine as a barrier to creating new, and more efficient vaccine technology.

 

Up until about a year ago the CDC’s mantra has been for healthy adults under the age of 65, in years when the vaccine is a good match to circulating strains, effectiveness ranges from 70%-90%.

 

A statement that at times was interpreted as `up to 90% effective’  by officials and the media. A quick Google this morning found the following statement on a major company’s website (link) from 2006.

 

Get a seasonal flu shot every year. The Centers for Disease Control and Prevention (CDC) report that getting a seasonal flu shot the best way to prevent the seasonal flu. In fact it's up to 90% effective in preventing the seasonal flu and even if you catch the seasonal flu, the immunity provided by the vaccine can make your case milder.

 

Not only does this site overstate the effectiveness of the seasonal flu jab, it fails to mention the CDC’s  disclaimer of `in healthy adults under the age of 65’. I can find plenty of instances of this 90% effectiveness meme being used, some as recently as August of this year (link)

 

A little more than a year ago the CDC updated their FAQ on Flu Vaccine effectiveness, and as part of a much longer detailed posting, lowered their estimate of the inactivated flu shot’s effectiveness to read:

 

. . . recent RCTs of inactivated influenza vaccine among adults under 65 years of age have estimated 50-70% vaccine efficacy during seasons in which the vaccines' influenza A components were well matched to circulating influenza A viruses.

 

A number that pretty much matched CIDRAP’s finding (see A Comprehensive Flu Vaccine Effectiveness Meta-Analysis) which would be released a couple of weeks later. That analysis showed the trivalent inactivated vaccine (TIV) had a combined efficacy of 59% among healthy adults (aged 18–65 years).

 

While these numbers are much lower than we would would like to see, 50%-60% protection is far superior to no protection at all.

 

Which is why I continue to get, and support getting, the seasonal flu vaccine.

 

All of which serves as prelude to some extended comments released yesterday by Dr. Peter Sandman on the CCIVI report and public health’s long-standing inclination to overstate the effectiveness of the flu vaccine.

 

For those unfamiliar with Dr. Sandman, he is a world renown expert on crisis communications, who along with his wife and colleague Dr. Jody Lanard, provide consulting services to individuals, organizations, and companies – often during their worst public relations nightmares.

 

Together they also produce a wealth of invaluable risk management advice on their website, which quite frankly should be second home for anyone involved in public relations or risk communications.

Peter Sandman Website logo

 

In the interests of full disclosure Dr. Sandman served on the CCIVI Expert Advisory Group and has worked with CIDRAP in various capacities in the past, points that he makes abundantly clear in his preface. 

 

What follows are excerpts from a lengthy email he sent to Lisa Schnirring of CIDRAP NEWS, in advance of the report’s release, for use in her news articles.


There is so much good content here, I find it difficult to pick and choose excerpts.  As you’ll see, from the title onward, Dr. Sandman does not mince words - so please - follow the link to read it in its entirety.

 

 

We’d Be Likelier to Develop a Better Flu Vaccine If Public Health Officials Didn’t Keep Misleading Everyone about the Flu Vaccine We Have

 

by Peter M. Sandman

(an October 14, 2012 email to Lisa Schnirring of CIDRAP News)

On October 15, 2012, CCIVI released its report, entitled “The Compelling Need for Game-Changing Influenza Vaccines.” The report argued that the current flu vaccine is sorely inadequate; that a key barrier to developing a better vaccine is the widespread judgment that the current one is fine; and that the main reason the vaccine’s effectiveness is so consistently overestimated is that public health officials keep saying it is better than it is.

<SNIP>

Chapter 7 does a fine job of documenting how public health – especially ACIP – overestimates and overstates the efficacy of the flu vaccine. There are really three criticisms here:

  • ACIP recommendations for ever-wider flu vaccination have been grounded in claims, assumptions, and judgments that the vaccine was more effective than it actually is.
  • Early on that was because good data weren’t available, but long after there were ever-better data showing that the flu vaccine wasn’t very effective, ACIP continued to speak and act as if it were – ignoring some studies, misinterpreting others, leaning too heavily on studies with big methodological flaws, relying on plausibility and expert judgment while claiming to be relying on sound science, etc.
  • In their zeal to encourage vaccination, ACIP, CDC, and the rest of the public health leadership kept telling the public (often via state and local public health officials and people’s personal doctors) that the flu vaccine worked better than it works.

<SNIP>

2. How do you think the report will be received? (Some of Chapter 7 sure reads like a GAO report. Lots of investigation work went into the analysis of ACIP’s recommendations.) What areas might see some early impact from the findings?

The central claim in the report is of course its claim that the flu vaccine is a lot less effective than most vaccines and a better one is badly needed.

 

Many in public health will find that claim difficult to embrace. But however reluctantly, I think they will embrace it. The Lancet I.D. study paved the way; in anticipation of that study’s publication, CDC stopped claiming 70–90% effectiveness in healthy adults under 65 and retreated to the much more supportable 50–70% estimate.

 

Now, sadly, CDC and many lower-level public health officials often provide no flu vaccine effectiveness estimate at all in their public communications, having learned that 70–90% is scientifically unsound but fearful that the more accurate 50–70% might undermine public acceptance. This is a small example of officials not trusting the public, which is a very large risk communication problem in public health. (See “Trust the Public with More of the Truth: What I Learned in 40 Years in Risk Communication.”)

 

(Continue . . .)

 

 

The CCIVI report and Dr. Sandman’s comments will undoubtedly discomfit many in the public health field, even if they privately accept their findings. 

 

There is, after all, legitimate concern that anti-vaccine activists will use this report as fodder for their propaganda machine.

 

But in reality, public health faces an even bigger challenge.

 

As I wrote earlier this year in in Science At The Crossroads, the public’s faith in science and technology is eroding. And during a public health emergency, that could prove disastrous.

 

One only has to look at the deep divisions over climate change, evolution, vaccine safety, nuclear power, and genetically modified food crops to realize just how wide this rift between the public and scientists has become.

 

Recent revelations regarding deceit and fraud in scientific research (see PNAS study Misconduct accounts for the majority of retracted scientific publications) have only served to intensify this mistrust.

 

Rekindling the public’s trust is paramount, and the first step in that direction is trusting the public with the truth (or at least, our best estimation of the truth at the time).

 

If the vaccine is only 60% effective, we need to embrace that number and promote it the same way we do seatbelts.

 

Seatbelts don’t guarantee you’ll walk away from a wreck, but they sure improve your odds.

 

Most people understand that, and buckle up.

 

I honestly believe that those who are inclined to get a flu shot will accept those limitations, while those who are vehemently against vaccines  . . .  well, they weren’t going to be persuaded by VE numbers, no matter how high they were.

 

I can’t help but remember what a terrific job the CDC’s Admiral Anne Schuchat - Director of the National Center For immunization and Respiratory Diseases - did during the summer and fall of 2009 briefing the press and the public day after day on the emerging H1N1 pandemic.

 

Her candor, ability to work `off script’ and willingness to concede the things they did not know about the virus were equal parts effective, comforting, and refreshing - and in my mind, anyway – constituted the CDC’s finest hour during that crisis.

 

I believe this type of straight talk should be the model for all public health messaging, even if inconvenient facts (like a VE rate of 60%) are less than comforting.

 

That it is only if you trust the public with the truth that you can win, and hold, their confidence. 

 

Anything less just deepens the rift of public distrust and plays into the hands of the critics.

»» Read More

CIDRAP: The Need For `Game Changing’ Flu Vaccines

image


# 6636

 

For those of us who promote influenza vaccines as a sensible - and extraordinarily safe (see Harvard Study Reaffirms Safety Of Flu Vaccine) – measure to help prevent the flu each year, there is one caveat we are always obliged to mention.  

 

The flu shot isn’t as nearly as effective as most other vaccines - and in some people (particularly the elderly) - may fail to produce protective levels of antibodies.

 

This is a problem we’ve covered many times before, including:

 

CID Study: Effectiveness Of 2010-11 Flu Vaccine

Study: Flu Vaccines And The Elderly

Flu Shots For The Elderly May Have Limited Benefits

 

 

In October of 2011, in A Comprehensive Flu Vaccine Effectiveness Meta-Analysis, Michael T. Osterholm and his team at CIDRAP produced the largest meta-analysis of influenza vaccine studies to date.

 

A few of their findings for the current flu vaccine:

 

TIV showed efficacy in preventing influenza during 8 of 12 flu seasons (67%) with a combined efficacy of 59% among healthy adults (aged 18–65 years).

 

And among children aged 2-7, the LAIV proved even more protective, showing efficacy in 9 out of 12 flu seasons (75%) with a pooled efficacy of 83%

 

The authors concluded that better vaccine technologies are sorely needed as evidence showed influenza vaccine effectiveness to be lower than had been publicly stated in the past. 

 

At best, today’s flu vaccines were shown to provide a moderate level of protection. Certainly better than no vaccination, but quite obviously, not nearly good enough.

 

Osterholm and his team are back today, with a truly impressive 160-page report that emphasizes the need for a revolution in vaccine technology.

 

 

The Compelling Need for Game-Changing Influenza Vaccines


An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future


Michael T. Osterholm, PhD, MPH, Nicholas S. Kelley, PhD, Jill M. Manske, PhD, MPH, Katie S. Ballering, PhD, Tabitha R. Leighton, MPH, Kristine A. Moore, MD, MPH

 

 

For those not ready to commit to reading a 160-page report, there is a 12-page Executive summary available.

 

At this point I’ll turn to the press release from CIDRAP, where Dr. Osterholm emphasizes the idea that our history of overestimating the effectiveness of the current vaccine serves as a barrier to developing new vaccine technologies.

 

 

New U of M-led analysis finds urgent need for new influenza vaccines

EMBARGOED until 10:00 a.m. CST, October 15, 2012


Laurel Herold, Academic Health Center, 612-624-2449,
hero0045@umn.edu
Justin Paquette, Academic Health Center, 612-626-7037, jpaquett@umn.edu

 

MINNEAPOLIS/ST. PAUL (October 15, 2012) – According to a new report from the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), current influenza vaccines offer less protection against seasonal influenza than previously reported. As a result, the misperception that current vaccines are highly effective in fighting influenza has become a barrier to creating new, more effective vaccines.

 

Innovative influenza vaccines currently in investigational research offer the potential of lasting, broad and potent protection against both seasonal and pandemic influenza, but substantial research and policy support is needed to further their development and evaluation.

 

In addition, the report finds that as part of an effort to reduce influenza illness and death, policy shifts toward a universal recommendation for influenza vaccination often were based on professional judgment and not on sound data.

 

The new report, The Compelling Need for Game Changing Influenza Vaccines from the CIDRAP Comprehensive Influenza Vaccine Initiative (CCIVI), follows a review of more than 12,000 peer-reviewed publications, documents, transcripts and notes dating back to 1936 and interviews and follow up with nearly 100 experts in influenza vaccine research, development, and use.

 

We urge people to get their flu shot. The present vaccines are the best interventions available for seasonal influenza,” said Michael T. Osterholm, Ph.D., M.P.H., University of Minnesota infectious disease expert and the CCIVI report’s lead author. “However, these vaccines do not offer consistent, high-level protection – especially in individuals at risk of medical complications or those aged older than 65 years. Unfortunately, these are the populations where we need the vaccines to work the best.  We need new influenza vaccines that work for everyone, most of the time.”
Researchers found that during some influenza seasons, current vaccines offer more protection for most of the population than being unvaccinated. However, compared to most routinely recommended vaccines, influenza vaccine protection is substantially lower.

 

“We can no longer accept the status quo with regard to influenza vaccine research and development,” added CCIVI expert advisory group chair, Alfred Sommer, Ph.D, Johns Hopkins Bloomberg School of Public Health, after reviewing the latest report. “Only with new game-changing vaccines can we ever really be prepared for the next influenza pandemic.”

(Continue . . .)

 

 

There is a natural reluctance for many health care providers to go into great detail regarding the protective value of the flu vaccine.

 

With a vaccine effectiveness rate of under 60%, it’s like trying to sell a bullet-proof vest designed to stop one out of every two bullets. Disclosures like that tend to create market resistance.

 

And so the tendency is to generalize, approximate, or gloss over the effectiveness issue.

 

 

This, Dr. Osterholm believes, creates the false illusion that the current vaccine technology is `good enough’. And that, during a severe pandemic influenza outbreak, could prove disastrous.

 

The study provides 10 key findings.

 

1. During some influenza seasons vaccination offers substantially more protection for most of the population than being unvaccinated; however, influenza vaccine protection is markedly lower than for most routinely recommended vaccines and is suboptimal.

 

2. A major barrier to the development of game-
changing influenza vaccines is the perception that current vaccines are already highly effective in
preventing influenza infection.

 

3. In an effort to reduce influenza morbidity and
mortality, over the last three decades the ACIP
has expanded the populations recommended to
receive influenza vaccine. These recommendations,
however, often were based on professional
judgment and not on scientifically sound data.

 

4. Novel-antigen influenza vaccines in investigational research offer the potential of
lasting, broad, and potent protection; however,
substantial research support is needed to further
develop and evaluate these vaccines.

 

5. The current US government regulatory process for approving influenza vaccines is primarily designed for incremental changes to existing vaccines and presents a barrier to the development of game-changing vaccines.

 

6. Substantial financial risks and inadequate
incentives create significant barriers to bringing
game-changing vaccines to market.

 

7. Coordinated partnerships involving national
governments, the pharmaceutical industry, the
investment community, and academia will be
critical to move such vaccines through clinical
trials and the licensure process.

 

8. Current policy goals for influenza vaccines focus
on increasing production capacity and have not
addressed key public health challenges related to
the effectiveness of current vaccines.

 

9. Significant policy, investment, organizational,
and leadership barriers must be overcome to
achieve novel-antigen game-changing influenza
vaccines.

 

10. Pandemic influenza remains a clear and
compelling threat to our national security and requires commensurate prioritization and an unprecedented coordinated effort among
government, academia, and the private sector to
mitigate this threat.

 

 

Given that this study challenges many long held beliefs, it will be interesting to see how it is received by the vaccine industry, public health officials, and ultimately, the public.

»» Read More

CDC Telebriefing on West Nile Virus

 

image

 

# 6510

 


A public health situation we’ve been following here for the past several weeks (see here, here, here, and here) was the subject of a CDC telebriefing today; the unusually high incidence of West Nile infections across the country, but most noticeably in Texas.

 

According to the CDC’s Dr. Lyle R. Petersen, director of the DVBID at the CDC, 2012 may be on track to be the worst yet in the 13 year history of the virus in the United States.

 

Yesterday, the CDC’s DVBID division updated their numbers through August 21st, indicating:

 

2012 West Nile virus update: as of August 21

Thus far in 2012, 47 states have reported West Nile virus infections in people, birds, or mosquitoes. A total of 1118 cases of West Nile virus disease in people, including 41 deaths, have been reported to CDC. Of these, 629 (56%) were classified as neuroinvasive disease (such as meningitis or encephalitis) and 489 (44%) were classified as non-neuroinvasive disease.

 

The 1118 cases reported thus far in 2012 is the highest number of West Nile virus disease cases reported to CDC through the third week in August since West Nile virus was first detected in the United States in 1999. Approximately 75 percent of the cases have been reported from 5 states (Texas, Mississippi, Louisiana, South Dakota, and Oklahoma) and almost half of all cases have been reported from Texas.

 

 

Of the 1118 cases, nearly half (n=537) are from Texas, and 26 deaths so far this year have been recorded in the Lone Star State. Hard hit Dallas county reported their 11th fatality yesterday.

 

Elsewhere across the nation, 38 other states have reported West Nile infections in humans, and deaths have been reported across 16 states.

 

Of note, Louisiana has reported 6 fatalities and Oklahoma has reported 3.

 


Today’s telebriefing featured Lyle R. Petersen, M.D. and the transcript should be posted on the CDC’s media site tonight or tomorrow (now available at this link).

 

Lisa Schnirring writing for CIDRAP NEWS has an excellent summary of today’s briefing:

 

CDC reports surge in US West Nile virus activity

Lisa Schnirring * Staff Writer

Aug 22, 2012 (CIDRAP News) – The United States is experiencing a dramatic rise in the cases of West Nile virus (WNV) infections over the past month, with record-setting numbers expected over the next several weeks and the US Centers for Disease Control and Prevention (CDC) warning people to take key preventive steps.

 

So far, 38 states have reported human cases, but the epicenter is Texas, which has reported half of the WNV infections. The CDC said so far it has received reports of 1,118 cases, including 629 people with the neuroinvasive form of the disease. Nationally, 41 deaths have been reported.

(Continue . . .)

 

 

 

Given that the WNV season doesn’t usually peak until mid-August, and it can take 2 to 3 weeks for symptoms to develop, many more cases are expected over the next few months.

 

While 80% of those infected don’t show symptoms, last week WEBMD carried a report (see New West Nile Threat: Kidney Disease) about research conducted by Baylor University West Nile expert Kristy O. Murray, PhD, DVM.

 

Dr. Murray’s research (see Persistent Infection with West Nile Virus Years after Initial Infection) suggests long-term sequelae may develop among a significant percentage of those who are infected with the West Nile Virus – even among those infected asymptomatically.

 

Dr. Murray was awarded an NIH grant in 2011 to study the effects of chronic WNV infection on the kidneys and central nervous system.

 

Reason enough to take seriously the recommendations from health departments across the nation that urge people to follow the `5 D’s’ of mosquito protection:

image

To find out about the West Nile threat in your area, you can visit the DVBID website below:

Links to State and Local Government West Nile Virus Web Sites

 Image: West Nile Virus Map of States with links to their West Nile Virus pages

And as a final note, the CDC recently updated their information on mosquito repellants.

Updated Information regarding Insect Repellents

»» Read More

CDC: Updated H3N2v Surveillance & Testing Guidance

 

image

Photo Credit CDC

 

# 6508

 

Nearly all of the recent cases of H3N2v infection in the Midwest have thus far been associated with exposure to pigs at state and county fairs. Admittedly, testing for the virus has been concentrated mostly among those with known recent swine contacts, and that may entail some bias.

 

It’s a logical place to start looking, given the swine-origin of the virus. But it’s a surveillance strategy that has the potential to miss other cases in the community.

 

Yesterday, in an attempt to cast a wider surveillance net, the CDC updated their guidance recommendations to state and local health departments on testing for the H3N2v virus.  

 

 

Interim Guidance for Enhanced Influenza Surveillance: Additional Specimen Collection for Detection of Influenza A (H3N2) Variant Virus Infections

Posted August 20, 2012

Summary

This document is an update to interim enhanced surveillance guidance first posted in December 2011. In light of the increasing numbers of cases of H3N2 variant virus (H3N2v) and increasing numbers of states reporting H3N2v cases, states should consider expanding surveillance to include rRT-PCR testing of specimens from ILINet providers statewide, and of specimens collected from people with unusual or severe presentations of ILI. States should also consider collection of specimens from outbreaks of ILI among children in child-care and school settings, since these settings have been associated with person-to-person H3N2v virus transmission in 2011. CDC will continue to evaluate new information as it becomes available and will update this guidance as needed.

<SNIP>

CDC would like state and local health departments to consider the following recommendations for influenza surveillance and testing.

  1. All state public health laboratories should use the CDC Human Influenza Real-Time rRT-PCR FLU Diagnostic Panel to screen specimens for InfA, InfB, and RP.
  2. Test all InfA-positive specimens with the CDC Influenza A Subtyping kit using all primer/probe sets: H1, H3, pdmInfA and pdmH1. Detailed guidance for testing can be found in the influenza surveillance diagnostic testing algorithm disseminated recently by Association of Public Health Laboratories  [27 KB, 1 page]. Specimens that are presumptive positive for H3N2v virus should be sent to CDC Influenza Division for additional testing as soon as possible.
  3. Conduct contact tracing of confirmed and probable influenza A (H3N2)v cases to gather more information about the epidemiology of the virus and modes of transmission. Contact tracing is essential to evaluate potential person-to-person transmission.
  4. Currently, while seasonal influenza viruses are circulating at low levels, CDC recommends increasing collection of specimens from patients with influenza-like-illness (ILI), and having these specimens sent to the state or local laboratory for rRT-PCR testing. States should specifically consider increasing collection of specimens across the state from patients presenting with ILI in the following high priority areas:
    1. All ILINet providers statewide.
    2. ILI outbreaks statewide, particularly among children in child care and school settings, since these settings were associated with person-to-person influenza A (H3N2)v virus transmission in 2011.
    3. Unusual or severe presentations of ILI statewide, including hospitalized persons.
    4. Medically attended ILI and acute respiratory infection (ARI), especially in children in counties or states where confirmed H3N2v cases have occurred.

 


With schools across the Midwest beginning their fall session this month, and scores of county and state fairs scheduled over the next couple of months, the need to pin down how this virus behaves – and whether any human-to-human transmission is occurring – increases.

 

Meanwhile, the debate over whether pigs should be excluded from public venues continues, as illustrated by this story that appeared last night on CIDRAP News, written by Lisa Schnirring.  

 

 

H3N2v infections spark debate about barring pigs from fairs

Lisa Schnirring * Staff Writer

Aug 21, 2012 (CIDRAP News) – The type of flu transmission occurring mainly in young people directly exposed to pigs at fairs this summer is unprecedented, and health officials should consider keeping pigs away from the events, according to one infectious disease expert who has gone on record with his concerns.

 

As Minnesota announced its first confirmed and suspected variant H3N2 (H3N2v) infections yesterday, just a few days before the start of its state fair, local and national media outlets such as the Canadian Press aired concerns from Michael Osterholm, PhD, MPH, director of the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP), publisher of CIDRAP News, who said that fair organizers should bar swine from fairs this year.

(Continue . . . )

»» Read More

EID Journal: Flu In Healthy-Looking Pigs

 

image

Credit Wikipedia


# 6497

 


Over the past month we’ve been watching a small but growing number of human infections with a novel H3N2v influenza virus - most of which are associated with direct contact with pigs being displayed at county and state fairs.

 

Efficient and sustained human-to-human transmission has not been established by the CDC, and so their recommendations at this time revolve around preventing disease transmission from pigs to humans.

 

Earlier this week the CDC issued advice to Fair organizers, that included:

 

Animal Health Recommendations:
  • Monitor animals daily for signs of illness, including discharge from nose and/or eyes, lethargy (sleepiness), no appetite, fever, or sometimes coughing. Ensure that a veterinarian, such as the fair vet or state vet, is notified of any ill animals.
  • Ill pigs, animals suspected or known to be infected with influenza viruses, and animals from herds with a recent history of respiratory disease should not be exhibited. They should be immediately isolated or sent home.

 

 

Yesterday, a dispatch appearing in the CDC’s EID Journal illustrated just how difficult identifying and separating influenza-infected pigs from the rest can be. 

 

It’s called:

 

Volume 18, Number 9—September 2012
Dispatch

Influenza A(H1N1)pdm09 Virus among Healthy Show Pigs, United States

Article Contents

Gregory C. Gray , Jeffrey B. Bender, Carolyn B. Bridges, Russell F. Daly, Whitney S. Krueger, Michael J. Male, Gary L. Heil, John A. Friary, Robin B. Derby, and Nancy J. Cox

Abstract

Within 5 months after the earliest detection of human influenza A(H1N1)pdm09 virus, we found molecular and culture evidence of the virus in healthy US show pigs. The mixing of humans and pigs at swine shows possibly could further the geographic and cross-species spread of influenza A viruses.

 

 

Asymptomatic carriage of viruses is not uncommon in humans, of course.  A few examples we’ve looked at in the past include:

 

  • During the 2009 pandemic I wrote They Walk Among Us, that looked at the difficulties of identifying those who might be infectious based on symptoms such as fever.
  • Earlier this year, in The Very Common Cold, we looked at a study of rhinovirus among college students tested over an 8 week period – that found asymptomatic infections led symptomatic infections by a factor of 4 to 1.
  • And last year, in EID Journal: Pre-Symptomatic Influenza Transmission, we saw evidence of presymptomatic spread of the H1N1 virus in three clusters in Japan, which also suggests that asymptomatic carriers ought to be able to spread the virus as well.

 

The idea that pigs might carry influenza viruses asymptomatically, therefore, is hardly surprising. But the amount of available scientific research has been limited.

 

Yesterday’s study found that nearly 1 in 5 healthy-looking pigs they tested were actually infected with a flu virus.

 

Last night Lisa Schnirring and Robert Roos of CIDRAP NEWS  wrote extensively on this study, and so at this point, I’ll simply invite you to read their excellent report.

 

 

Study finds flu in healthy-looking pigs at state fairs

Lisa Schnirring and Robert Roos * Staff Writers

Aug 15, 2012 (CIDRAP News) – Testing of a sampling of pigs shown at the Minnesota State Fair during the 2009 H1N1 influenza pandemic revealed that 19% of them were infected with flu viruses, even though they looked healthy, according to a new study.

 

The findings highlight the challenges of preventing pigs and humans from passing flu viruses back and forth at fairs and swine shows, especially this summer when several states are tracking human illnesses from a novel H3N2 virus that has been detected in both pigs and people.

(Continue . . . )

 

 

During the 2009 H1N1 pandemic Japan, India, and China were among the nations that attempted to identify, interdict, and isolate those who might be carrying the H1N1 virus when they entered their country.

 

While their efforts may have slowed the introduction of the virus, they certainly didn’t stop it.  Earlier blogs on these attempts include:

 

Japan: Quarantine At Ports Ineffective Against Pandemic Flu
Experts: Extreme Measures Won’t Stop The Flu

 

Their failure was likely due to the large number of presymptomatic, and asymptomatic carriers of the virus that arrived without showing signs of illness.

 

And the same is likely true with pigs on display at county fairs this fall.

 

Removing symptomatic pigs certainly makes sense - and will certainly reduce the risks of spreading the virus - but it is unlikely to totally eliminate it.

 

Which means that additional human cases of H3N2v are likely, even with the enhanced biosecurity measures in place at county fairs.

 

Before anyone gets freaked out over the risks of going to the county fair, so far this summer there have been only about 200 confirmed cases of this H3N2v flu, involving 5 brief hospitalizations and no deaths. 

 

During roughly the same time period, there have been nearly 700 West Nile Infections, involving hundreds of hospitalizations, and 26 deaths.

 

So if you are looking to lower your risks of illness when you go to the county fair this fall, it only makes sense to carry and use a hand sanitizer, and avoid eating or drinking around animal displays. 

 

But to avoid serious illness, the better advice is to wear an insect repellant whenever you go outside, as your risks of contracting viral illness are greater right now from infected mosquitoes, than they are from sick pigs.

 

image

»» Read More

CIDRAP: Children & Middle-Aged Most Susceptible To H3N2v

image

Credit Wikipedia

 

# 6489

 


Robert Roos of CIDRAP has an excellent report on a study – published on Aug 7th in The Journal of Infectious Diseases – that looks at pre-existing, and vaccine-induced immunity to the emerging H3N2v swine flu virus by age cohorts.

 

This serological study, conducted in Canada, is called :

 

Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v

Danuta M. Skowronski, Naveed Z. Janjua, Gaston De Serres3, Dale Purych, Vladimir Gilca, David W. Scheifele, Marc Dionne, Suzana Sabaiduc, Jennifer L. Gardy, Guiyun Li, Nathalie Bastien, Martin Petric, Guy Boivin and Yan Li

 

 

Below is Robert’s report on these findings, and as I’m hardly likely to improve upon his work, I’ll simply invite you to follow the link below and read:

 

Study: Children, middle-aged most vulnerable to variant H3N2

Robert Roos * News Editor

Aug 10, 2012 (CIDRAP News) – A serologic study from Canada suggests that children and middle-aged adults have little or no immunity to the swine-origin variant H3N2 influenza virus (H3N2v), but about half of adolescents and young adults have some degree of immunity as measured by antibody levels.

(Continue . . .)

 


Robert’s story mentioned earlier studies with similar findings, and you can find details on them in these earlier blogs:

 

Last April in MMWR: Antibodies Cross-Reactive to Influenza A (H3N2) Variant Virus, we saw a study that found that children under the age of ten were practically devoid of antibodies to this virus, and were likely the most susceptible to infection.

 

A few months before, in Eurosurveillance: Older People May Be Susceptible To The H3N2v Virus), we saw evidence that the moderate levels of immunity detected in adolescent and young adult populations declined with age.

 

In other H3N2v news, Lisa Schnirring of CIDRAP has a excellent roundup, including the release of new interim clinician guidelines, the poor reliability of RIDTs (Rapid Influenza Detection Tests) with this virus, and an age breakdown of confirmed cases that now includes 10 adults.

 

CDC updates novel H3N2 info for clinicians

Lisa Schnirring * Staff Writer

Aug 10, 2012 (CIDRAP News) – The US Centers for Disease Control and Prevention (CDC) today reported that it has received 153 reports of novel H3N2 infections (H3N2v) since illnesses started surfacing in the middle of July, nearly all of them in people who had contact with pigs or were around pigs at fairs.

 

In another development, the CDC issued new information on H3N2v for clinicians, including an evaluation of rapid influenza tests that found their sensitivity varies greatly, and the agency urged clinicians not to use negative results as the basis for treatment.

(Continue . . . )

 

 

A blogger’s Note:

 

The slow emergence of this swine H3N2v virus into the human population is a fascinating story, and one that certainly deserves ongoing coverage.  But at the same time, the last thing this story needs is unwarranted hype.

 

According to the CDC, this virus has not adapted well enough to human physiology to spark a pandemic.  Nearly all confirmed cases appear to be the result of direct contact with an infected pig.

 

Sustained and efficient Human-to-Human transmission does not appear to be occurring at this time.

 

The caveat being, that over time, that could change.

 

For now, this virus is less a public health threat story and more an opportunity for us to learn how these types of viruses evolve in swine and (on rare occasion) seep into the human population.

 

A cautionary tale, if you will, on how nature’s laboratory is open 24/7 - constantly trying out new viral combinations - looking for an evolutionary advantage.

 

The dilemma, from my standpoint, is how to cover this story responsibly. 

 

Rather than rush to post a blog every time we get an updated case count, for my own sanity, I’ve decided only to blog on the H3N2v virus when there is something more substantial to report.

 

This weekend I’ll explore the possibility of keeping a daily update `State Confirmed H3N2v Cases’ in my sidebar, at least until that becomes too unwieldy.

 

Even so, I’m sure H3N2v will get ample attention in these pages.

 

As we wait to see what this H3N2v virus ends up doing - between seasonal flu, bird flu, swine flu, seal flu, and bat flu, plus non-flu related stories - I’m confident there will be no shortage of topics to blog about.

»» Read More

Mexico: High Path H7 In Jalisco

image

Photo Credit – FAO

 

# 6506

 

 

Last night Lisa Schnirring writing for CIDRAP NEWS  brought us details on the first highly pathogenic bird flu outbreak in Mexico in nearly two decades.  The last time was during the mid-1990s, and the virus was H5N2.

 

This time, the culprit it is H7N3.

 

Follow the link below to read  Lisa’s excellent report, after which I’ll return with a bit more.

 

Tests reveal high-path H7N3 in Mexican poultry farm outbreaks

Lisa Schnirring * Staff Writer

Jun 26, 2012 (CIDRAP News) – Mexican veterinary authorities are intensifying avian influenza control efforts in a region that houses several large commercial farms after further tests determined that the strain responsible for more than 200,000 bird deaths at three farms is the highly pathogenic H7N3 subtype.

(Continue . . . )

 



While there are a number of avian flu viruses circulating in the wild, the OIE only requires that H5s and H7s be reported due to their known ability to mutate from a low pathogenic virus to highly pathogenic virus.

 

When it comes to avian influenzas, the H5N1 virus gets the bulk of the headlines, and rightfully so. While a matter of some controversy (see Revisiting The H5N1 CFR Debate), among known human cases, the mortality rate has been a staggering 60%.

 

Other strains that have demonstrated at least some ability to infect humans include H7, H9, H10, and H11. Fortunately, most of the time these rare infections have produced only mild flu symptoms (sometimes only localized conjunctivitis).

 

Last April, in EID Journal: Human Infection With H10N7 Avian Influenza we looked at some recent H10 infections, and in 2011 we explored A Little Background On H11 Avian Influenzas.

 

For now, however, these viruses are primarily a threat to the poultry industry, and to a lesser extent, people working in direct contact with infected fowl.

 

Although global surveillance and reporting on novel avian viruses in humans is spotty at best, some known H7 cases include:

 

  • In 2003 an outbreak of H7N7 at a poultry farm in the Netherlands went on to infect at least 89 people. Most of the victims were only mildly affected, but one person died.
  • In 2004 two people in British Columbia tested positive for H7N3 (see Health Canada Report) during an outbreak that resulted in the culling of 19 million birds.
  • In 2006 and 2007 there were a small number of human infections in Great Britain caused by H7N3 (n=1)  and H7N2 (n=4), again producing mild symptoms.

 

For now, H7 avian influenzas are presumed to pose a low public health threat, which may leave you wondering why all this fuss over this outbreak of H7N3?

 

The H7s, like all influenza viruses, are constantly mutating and evolving.  

 

While considered mild today, there are no guarantees that the virus won’t pick up virulence over time, or reassort with another virus and increase its affinity for humans.

 

Four years ago, we saw a study in PNAS that indicated that the H7 virus might just be moving more towards adapting to humans.

 

Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility

You can read more about this in a couple of blogs from 2008, H7's Coming Out Party and H7 Study Available Online At PNAS.

 

The last pandemic, you will recall,  came out of left field; from a region of the world (North America), host species (swine), and influenza strain (H1N1) all considered unlikely to spark a global epidemic.

 

Which is why we pay attention whenever there is an outbreak of a novel flu virus for which mankind may have little or no immunity.

»» Read More

Updating Public Health Practices (PHP)

 

image

 


# 6381

 

 

Every few months I try to highlight the Public Health Practices project (formerly Promising Practices), a freely accessible repository of public health tools and strategies, sponsored by CIDRAP at the University of Minnesota, in partnership with the Association of State and Territorial Health Officials (ASTHO).

 

 

I’ve been remiss in not mentioning them since late last year, especially since they are currently seeking feedback from visitors on how they are doing.

 

After you’ve explored their site, there is a short survey they would appreciate your answering.

 

 

Over the past year Public Health Practices has broadened its original scope to include more than just pandemic response. You’ll find tools and practices that cover a wide range of public health concerns, including chemical, radiological, and natural disasters.

 

image

 

In addition to the constantly expanding website, there is also a monthly email newsletter you can sign up for.

 

The About Us page provides an overview of the mission of the Public Health Practices website:

 

Features of Public Health Practices include:

  • More than 300 public health practices in 9 categories of emergency preparedness and disaster response from state and local health agencies, community-based organizations, and colleges and universities.
  • In-depth stories on how state and local projects were created, communications materials in more than 40 languages, and tools like job action sheets and media campaigns.
  • Expert reviewers' commentary on a practice's effectiveness, reach, sustainability, feasibility, and transferability. Please note: expert review is only available for a select number of practices.
  • A regular e-newsletter featuring our newest practices and other updates from the CIDRAP Public Health Practices staff.
  • The ability to search for practices based on geography, available languages, and key topics in preparedness and response.

 

 

If you are interested in starting a community public health, preparedness, or response program - or one for a college or university - a visit to this website could save you and your organization or agency a lot of time, money, and aggravation.

 

Some recent additions to the site include:

 

Recent Practices

Curriculum trains children to act as disaster preparedness ambassadors to their families

 

Guidance helps integrate concerns about sexual violence into the roles and procedures of disaster responders

 

Parochial Armenian schools develop and implement an earthquake preparedness program

 

Framework provides strategies for addressing resource scarcity in hospitals and clinics during a regional response

 

Toolkit paves the way for hospitals to meet children's needs during a disaster

 

Partnership with Civil Air Patrol allows winter transport of emergency medications to Michigan's Upper Peninsula

 

 

Whether you are looking for a specific solution, or simply looking for muse to inspire your organization’s emergency preparedness efforts, visiting Public Health Practicesand returning often – will likely pay tremendous dividends.

 

Highly recommended.

»» Read More

TEDx UMN: Rethinking Influenza Vaccines

 

 


# 6298

 

Constant readers are aware that I am an unabashed fan of TED Talks, and have featured a number of them in this blog.  TED stands for Technology, Entertainment, Design, and participants are invited to `give the 18 minute talk of their lives’ before a live audience.

 

I was first turned onto the TED Talks when a friend sent me a link to the winner of 2006’s TED Prize, Dr. Larry Brilliant's presentation on his dream of a new global system that can identify and contain pandemics before they spread. If you’ve never seen this speech, I urge you to watch it now.

 


There are now over 1100 TED talks on a myriad of subjects, freely available for viewing on the TED Website, and you could spend weeks exploring the site. You can also subscribe to them on itunes or view them on Youtube.

 

So popular have the official TED TALKS become that local, independently organized versions of them (called TEDx) have sprung up around the world. 

 

TEXx describes their mission as:

 

Created in the spirit of TED’s mission, “ideas worth spreading,” the TEDx program is designed to give communities, organizations and individuals the opportunity to stimulate dialogue through TED-like experiences at the local level. TEDx events are fully planned and coordinated independently, on a community-by-community basis

 

And now there are hundreds of local TEDx events held around the world every month. Their website provides information on upcoming events.

 

Last weekend the University of Minnesota held a day-long TEDx event (TEDxUMN) , which was live-streamed on the internet, and those videos are now online.

 

While I would invite you to view all of the talks, I wanted to call attention to one in particular, delivered by Nick Kelley -  preparedness program coordinator at CIDRAP – on Rethinking Influenza Vaccines.

 


The TEDxUMN talks are archived in two videos on this page, and you’ll find Nick’s in the second (bottom) video, at time stamp 2:16:35

 

image

 

Nick’s message is that influenza vaccines – while providing modest (59%) protection in healthy adults (under 65) – are in dire need of improvement. Worse, our inability to produce vaccines quickly seriously limits their value in a pandemic.

 

Despite these deficits, today’s flu vaccine remain our best weapon against influenza.

 

Nick argues that our acceptance of today’s vaccine technology as being `good enough’ serves as a psychological barrier to investing in, and developing, better vaccine technologies.

 

I’ll not give away the rest of his talk.

 

Follow this link to watch Nick’s entire presentation, and while you are at it, take a look at some of the other dozen plus TEDxUMN presentations.

 

 


Personal Note:  I’ll be away from my desk for much of the next three days, and while I’ll have my laptop with me, blogging and updates to this site may be light until Friday.

As always, Crofsblog, Arkanoid Legent, FluTrackers, the Flu Wiki  and Maryn McKenna’s Superbug Blog are terrific resources in Flublogia. 

»» Read More